TNSN03147A1 - Formes cristallines de sel de calcium (2 :1) d'acide [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1-h-pyrrole-1-heptanoique (atorvastatine) - Google Patents

Formes cristallines de sel de calcium (2 :1) d'acide [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1-h-pyrrole-1-heptanoique (atorvastatine)

Info

Publication number
TNSN03147A1
TNSN03147A1 TNPCT/IB2002/001796A TNSN03147A TNSN03147A1 TN SN03147 A1 TNSN03147 A1 TN SN03147A1 TN SN03147 A TNSN03147 A TN SN03147A TN SN03147 A1 TNSN03147 A1 TN SN03147A1
Authority
TN
Tunisia
Prior art keywords
atorvastatine
phenylamino
methylethyl
fluorophenyl
pyrrole
Prior art date
Application number
TNPCT/IB2002/001796A
Other languages
English (en)
Inventor
Stephen Robert Byrn
David Andrew Coates
Karen Sue Gushurst
Henry Grant Ii Morrison
Aeri Park
Petinka Ivanova Vlahova
Zheng Jane Li
Joseph Francis Krzyzaniak
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23166039&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN03147(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of TNSN03147A1 publication Critical patent/TNSN03147A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

FORMES CRISTALLINES NOUVELLES DU SEL HEMICALCIQUE D'ACIDE [R-(R*,R*)]-2-(4-FLUOROPHENYL)- BETA - DIHYDROXY -5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)-CARBONYL]-1H-PYRROLE-1-HEPTANOدQUE (ATORVASTATINE), APPELEES FORME V, FORME VI, FORME VII, FORME VIII, FORME XIX, FORME X, FORME XI, FORME XII, FORME XIII, FORME XIV, FORME XV, FORME XVI, FORME XVII, FORME XVIII ET FORME XIX. CARACTERISEES PAR LEUR DIFFRACTION DES RAYONS X SUR POUDRE, RMN A L'ETAT SOLIDE ET/OU SPECTROSCOPIE RAMAN SONT DECRITES. TOUT COMME DES PROCEDES POUR LEUR PREPARATION ET DES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT. UTILES COMME AGENTS POUR LE TRAITEMENT DE L'HYPERLIPIDEMIE, L'HYPERCHOLESTEROLEMIE, L'OSTEOPOROSE ET LA MALADIE D'ALZHEIMER.
TNPCT/IB2002/001796A 2001-06-29 2003-07-08 Formes cristallines de sel de calcium (2 :1) d'acide [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1-h-pyrrole-1-heptanoique (atorvastatine) TNSN03147A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30204901P 2001-06-29 2001-06-29

Publications (1)

Publication Number Publication Date
TNSN03147A1 true TNSN03147A1 (en) 2005-12-23

Family

ID=23166039

Family Applications (1)

Application Number Title Priority Date Filing Date
TNPCT/IB2002/001796A TNSN03147A1 (en) 2001-06-29 2003-07-08 Formes cristallines de sel de calcium (2 :1) d'acide [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1-h-pyrrole-1-heptanoique (atorvastatine)

Country Status (40)

Country Link
US (5) US6605729B1 (fr)
EP (2) EP3009423A3 (fr)
JP (2) JP3965155B2 (fr)
KR (1) KR100609371B1 (fr)
CN (2) CN1524073A (fr)
AP (1) AP1571A (fr)
AR (1) AR036118A1 (fr)
AU (1) AU2002258092B2 (fr)
BG (1) BG108393A (fr)
BR (1) BR0210666A (fr)
CA (1) CA2450111C (fr)
CR (2) CR7170A (fr)
CZ (1) CZ20033478A3 (fr)
DO (1) DOP2002000413A (fr)
EA (1) EA005317B1 (fr)
EC (1) ECSP034928A (fr)
EE (1) EE200300597A (fr)
ES (1) ES2558565T3 (fr)
GE (1) GEP20053546B (fr)
HR (1) HRP20031039A2 (fr)
HU (1) HUP0400381A2 (fr)
IL (1) IL158790A0 (fr)
MA (1) MA27044A1 (fr)
MX (1) MXPA03010266A (fr)
MY (1) MY122907A (fr)
NO (1) NO326170B1 (fr)
NZ (1) NZ529557A (fr)
OA (1) OA12636A (fr)
PA (1) PA8549501A1 (fr)
PE (1) PE20030124A1 (fr)
PL (1) PL367943A1 (fr)
RS (1) RS100003A (fr)
SK (1) SK16002003A3 (fr)
SV (1) SV2003001144A (fr)
TN (1) TNSN03147A1 (fr)
TW (1) TWI319396B (fr)
UA (1) UA74075C2 (fr)
UY (1) UY27359A1 (fr)
WO (1) WO2003004470A1 (fr)
ZA (1) ZA200308731B (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
ES2167587T3 (es) 1995-07-17 2002-05-16 Warner Lambert Co Forma cristalina de la sal hemicalcica del acido (r-(r*,r*))-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)-1h-pirrol-1-heptanoico (atorvastatina).
US20080275104A1 (en) * 1997-11-25 2008-11-06 Musc Foundation For Research Development Methods of treating juvenile type 1 diabetes mellitus
US20040072138A1 (en) * 1997-11-25 2004-04-15 Medical University Of South Carolina Attenuation of ischemia/reperfusion injury
WO1999026657A1 (fr) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibiteurs de la monoxyde d'azote-synthase
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
EP1332130A4 (fr) * 2000-11-03 2004-01-21 Teva Pharma Atorvastatine hemicalcique forme vii
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CA2431068C (fr) * 2000-12-27 2008-06-10 Ciba Specialty Chemicals Holding Inc. Formes cristallines d'atorvastatine
CZ20033478A3 (cs) * 2001-06-29 2004-10-13 Warner@Lambertácompanyállc Krystalické formy vápenaté soli }@�B [R@}RgŹRgB]@}@fluorofenylB@betaŹ@delta@dihydroxy@Q@}�@methylethylB@fenyl[}fenylaminoBkarbonyl]@�H@pyrrol@�@heptanové kyseliny }atorvastatinB
US7074818B2 (en) * 2001-07-30 2006-07-11 Dr. Reddy's Laboratories Limited Crystalline forms VI and VII of Atorvastatin calcium
US20060020137A1 (en) * 2001-11-29 2006-01-26 Limor Tessler Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
AU2003217653A1 (en) * 2002-02-15 2003-09-09 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix
KR20090045420A (ko) * 2002-02-19 2009-05-07 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴 헤미-칼슘 용매화합물의 탈용매화
CA2491051A1 (fr) * 2002-09-03 2004-03-18 Morepen Laboratories Limited Forme vi de calcium d'atorvastatine ou hydrates de cette derniere
EP1424324A1 (fr) * 2002-11-28 2004-06-02 Teva Pharmaceutical Industries Limited Forme cristalline F de calcium d'atorvastatine
WO2004050618A2 (fr) * 2002-11-28 2004-06-17 Teva Pharmaceutical Industries Ltd. Forme cristalline
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
JP2007516294A (ja) * 2003-12-23 2007-06-21 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 炎症性の疾患または症状の予防および治療のための方法および組成物
CA2560282A1 (fr) * 2004-03-17 2005-09-29 Ranbaxy Laboratories Limited Forme cristalline d'hemi-calcium d'atorvastatine
EP1727795B1 (fr) 2004-03-17 2012-02-15 Ranbaxy Laboratories Limited Procede de production d'atorvastatine calcique sous forme amorphe
CA2649054A1 (fr) 2004-05-05 2005-11-10 Pfizer Products Inc. Formes salines d'acide [r-(r*, r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoique
MX2007000765A (es) 2004-07-20 2007-03-28 Warner Lambert Co Formas cristalinas de sal de calcio del acido (r-(r*, r*))-2- (4-fluorofenil)- beta,gama- dihidroxi-5- (1-metiletil)-3 -fenil-4-((fenilamino) (carbonil)-1ih -pirrol-1- heptanoico (2:1).
TWI321132B (en) * 2004-09-28 2010-03-01 Teva Pharma Process for preparing forms of atorvastatin calcium substantially free of impurities
MX2007004722A (es) * 2004-10-28 2007-06-15 Warner Lambert Co Procedimiento para formar atorvastatina amorfa.
WO2006048894A1 (fr) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Nouvelles formes cristallines de calcium d'atorvastatine et procedes de fabrication
CA2588216A1 (fr) * 2004-11-22 2006-05-26 Dexcel Pharma Technologies Ltd. Formulations d'atorvastatine stables
EP1819319A1 (fr) * 2004-12-02 2007-08-22 Warner-Lambert Company LLC Compositions pharmaceutiques d'atorvastatine amorphe et leur procede de preparation
EP1688850A1 (fr) 2005-02-07 2006-08-09 Sony Ericsson Mobile Communications AB Analyseur générique pour les dispositifs électroniques
US8506646B2 (en) * 2005-04-29 2013-08-13 Warsaw Orthopedic, Inc. Multi-purpose medical implant devices
US8092464B2 (en) * 2005-04-30 2012-01-10 Warsaw Orthopedic, Inc. Syringe devices and methods useful for delivering osteogenic material
PT1957452E (pt) 2005-11-21 2010-05-25 Warner Lambert Co Novas formas de ácido [r-(r*,r*)]-2-(4-fluorofenil)-b,b--di-hidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)-carbonil]-1h-pirrole-1-heptanóico magnésico
WO2007058664A1 (fr) * 2005-11-21 2007-05-24 Teva Pharmaceutical Industries Ltd. Formulation d'atorvastatine
EP1923057A1 (fr) * 2005-11-21 2008-05-21 Teva Pharmaceutical Industries Ltd Formule pharmaceutique atorvastanine
US8080672B2 (en) 2005-12-13 2011-12-20 Teva Pharmaceutical Industries Ltd. Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
US7834195B2 (en) * 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
KR100878140B1 (ko) * 2007-01-29 2009-01-12 한미약품 주식회사 아토바스타틴의 스트론튬염 또는 이의 수화물, 및 이를포함하는 약학 조성물
WO2008108572A1 (fr) * 2007-03-02 2008-09-12 Dong-A Pharm. Co., Ltd. Nouvelles formes cristallines de dérivés d'acide pyrrolylheptanoïque
WO2008112887A1 (fr) * 2007-03-13 2008-09-18 Musc Foundation For Research Development Procédés de traitement du diabète sucré de type 1
WO2008123953A1 (fr) * 2007-04-02 2008-10-16 Merck & Co., Inc. Composé anti-hypercholestérolémique
DE102007052071A1 (de) 2007-10-30 2009-05-07 Stada Arzneimittel Ag Stabilisiertes Atorvastatin
CN101973922B (zh) * 2009-05-27 2013-01-23 天津和美生物技术有限公司 阿伐他汀半锶盐多晶型物、其制备和作为HMG-CoA酶抑制剂的应用
WO2011028309A1 (fr) 2009-09-04 2011-03-10 University Of Toledo Procédés de fabrication de bêta-lactones optiquement pures à partir d'aldéhydes et compositions obtenues par ces procédés
CZ201039A3 (cs) 2010-01-19 2011-07-27 Zentiva, K. S Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
CN103702982A (zh) * 2011-07-01 2014-04-02 中化帝斯曼制药有限公司荷兰公司 阿托伐他汀半钙的超细晶体
CN104945300B (zh) * 2015-06-17 2017-05-10 北京嘉林药业股份有限公司 一种ⅰ型阿托伐他汀钙的纯化方法
CN104983702A (zh) * 2015-07-23 2015-10-21 青岛蓝盛洋医药生物科技有限责任公司 一种治疗高胆固醇血症的药物阿托伐他汀钙组合物片剂
US10450957B2 (en) 2017-01-23 2019-10-22 United Technologies Corporation Gas turbine engine with heat pipe system
WO2020013330A1 (fr) * 2018-07-13 2020-01-16 協和発酵バイオ株式会社 Cristal de non-solvate d'acide eucomique et son procédé de production

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
EP0680320B1 (fr) 1993-01-19 1999-04-14 Warner-Lambert Company Formulation ci-981, orale, stable et son procede de preparation
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
ES2167587T3 (es) 1995-07-17 2002-05-16 Warner Lambert Co Forma cristalina de la sal hemicalcica del acido (r-(r*,r*))-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)-1h-pirrol-1-heptanoico (atorvastatina).
HRP960312B1 (en) * 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
US6087511A (en) 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
TR199900191T2 (xx) 1996-07-29 1999-04-21 Warner-Lambert Company (S)-3,4-Dihidroksibutirik asitin korumal� esterlerinin sentezi i�in geli�tirilmi� proses.
IN191236B (fr) 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
JP2003514798A (ja) * 1999-11-17 2003-04-22 テバ ファーマシューティカル インダストリーズ リミティド アトルバスタチンカルシウムの多形
US7411075B1 (en) * 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
SI20425A (sl) 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
MXPA02004078A (es) * 1999-12-17 2002-10-11 Warner Lambert Res & Dev Un proceso a escala industrial para producir sal de hemi calcio de trihidrato de atorvastatin cristalino.
WO2001044181A1 (fr) * 1999-12-17 2001-06-21 Warner Lambert Research And Development Ireland Limited Procede pour produire de l'atorvastatine calcique cristallin
EP1332130A4 (fr) * 2000-11-03 2004-01-21 Teva Pharma Atorvastatine hemicalcique forme vii
AU2002232891B2 (en) * 2000-11-16 2006-12-14 Teva Pharmaceutical Industries Ltd. Hydrolysis of [R(R*,R*)]-2-(4-fluorophenyl)-beta,delta -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CA2431068C (fr) * 2000-12-27 2008-06-10 Ciba Specialty Chemicals Holding Inc. Formes cristallines d'atorvastatine
WO2002057228A1 (fr) 2001-01-17 2002-07-25 Biocon India Limited Atorvastatine calcique
WO2002057229A1 (fr) 2001-01-19 2002-07-25 Biocon India Limited FORME V CRISTALLINE DE SEL HEMICALCIQUE D'ACIDE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIQUE (ATORVASTATINE)
SI20814A (sl) 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
IN190564B (fr) 2001-04-11 2003-08-09 Cadila Heathcare Ltd
GB0111077D0 (en) 2001-05-04 2001-06-27 Biochemie Gmbh Organic compounds
CZ20033478A3 (cs) * 2001-06-29 2004-10-13 Warner@Lambertácompanyállc Krystalické formy vápenaté soli }@�B [R@}RgŹRgB]@}@fluorofenylB@betaŹ@delta@dihydroxy@Q@}�@methylethylB@fenyl[}fenylaminoBkarbonyl]@�H@pyrrol@�@heptanové kyseliny }atorvastatinB
US7074818B2 (en) * 2001-07-30 2006-07-11 Dr. Reddy's Laboratories Limited Crystalline forms VI and VII of Atorvastatin calcium
US8080672B2 (en) * 2005-12-13 2011-12-20 Teva Pharmaceutical Industries Ltd. Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
US20070265456A1 (en) * 2006-05-09 2007-11-15 Judith Aronhime Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms

Also Published As

Publication number Publication date
UA74075C2 (en) 2005-10-17
HRP20031039A2 (en) 2005-10-31
MY122907A (en) 2006-05-31
EA200301243A1 (ru) 2004-06-24
PL367943A1 (en) 2005-03-07
EA005317B1 (ru) 2004-12-30
KR100609371B1 (ko) 2006-08-08
JP2005501032A (ja) 2005-01-13
CN101215253A (zh) 2008-07-09
JP3965155B2 (ja) 2007-08-29
AP2003002936A0 (en) 2003-12-31
PA8549501A1 (es) 2003-09-05
US7144915B2 (en) 2006-12-05
CR9741A (es) 2008-10-31
CZ20033478A3 (cs) 2004-10-13
OA12636A (en) 2006-06-15
NZ529557A (en) 2005-05-27
ES2558565T3 (es) 2016-02-05
IL158790A0 (en) 2004-05-12
JP2007182460A (ja) 2007-07-19
US20040054193A1 (en) 2004-03-18
MXPA03010266A (es) 2004-03-10
WO2003004470A1 (fr) 2003-01-16
UY27359A1 (es) 2003-04-30
MA27044A1 (fr) 2004-12-20
ECSP034928A (es) 2004-02-26
EP3009423A3 (fr) 2016-12-28
NO20035675D0 (no) 2003-12-18
KR20040014583A (ko) 2004-02-14
US6605729B1 (en) 2003-08-12
EP1423364B1 (fr) 2015-11-04
TWI319396B (en) 2010-01-11
ZA200308731B (en) 2004-11-10
US20060241169A1 (en) 2006-10-26
US20080287521A1 (en) 2008-11-20
DOP2002000413A (es) 2003-07-15
AU2002258092C1 (en) 2003-01-21
HUP0400381A2 (hu) 2004-09-28
EE200300597A (et) 2004-02-16
GEP20053546B (en) 2005-06-10
PE20030124A1 (es) 2003-02-12
CA2450111A1 (fr) 2003-01-16
AP1571A (en) 2006-02-10
US20080214651A1 (en) 2008-09-04
AR036118A1 (es) 2004-08-11
SV2003001144A (es) 2003-03-18
CA2450111C (fr) 2006-02-07
CR7170A (es) 2004-02-23
AU2002258092B2 (en) 2007-05-17
SK16002003A3 (sk) 2004-12-01
EP3009423A2 (fr) 2016-04-20
NO326170B1 (no) 2008-10-13
BR0210666A (pt) 2004-10-05
RS100003A (en) 2007-02-05
EP1423364A1 (fr) 2004-06-02
BG108393A (bg) 2004-12-30
CN1524073A (zh) 2004-08-25

Similar Documents

Publication Publication Date Title
TNSN03147A1 (en) Formes cristallines de sel de calcium (2 :1) d'acide [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1-h-pyrrole-1-heptanoique (atorvastatine)
HRP960313B1 (en) Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
NZ312907A (en) Crystalline [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl
EP2540704A3 (fr) Formes de sel de bénéthamine avec d'atorvastatine
CA2522899A1 (fr) Formes cristallines de sel hemicalcique d'acide [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoique (2:1)(atorvastatine)
TH61086A (th) รูปแบบผลึกของเกลือแคลเซียม (2